Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000024339
JPRN-UMIN000024339
Completed
N/A

Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:open-label study - Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities

ational Hospital Organization Hizen Psychiatric Center0 sites7 target enrollmentOctober 7, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAutism spectrum disorder severe intellectual disabilities

Overview

Phase
N/A
Intervention
Not specified
Conditions
Autism spectrum disorder severe intellectual disabilities
Sponsor
ational Hospital Organization Hizen Psychiatric Center
Enrollment
7
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 7, 2016
End Date
March 31, 2018
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ational Hospital Organization Hizen Psychiatric Center

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •CARS\-TV less than 30 points self\-standing position impossible Weighing less than 20kg History of status epilepticus Possibility of pregnancy Body exhaustion and advanced inspection value or more

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
Intranasal Oxytocin for Autism Spectrum Disorder and Comorbid Severe Intellectual Disabilities:Open-label long term studyAutism Spectrum Disorder Severe intellectual disabilities
JPRN-UMIN000028650ational Hospital Organization Hizen Psychiatric Center3
Recruiting
Phase 2
Oxytocin in Preschoolers with Autism receiving Social Learning TherapyAutism Spectrum DisordersMental Health - Autistic spectrum disorders
ACTRN12618001029280niversity of Sydney132
Active, Not Recruiting
Phase 1
The use of Oxytocin for Autism Spectrum Disorders: Investigating theeffect on behavior and at the level of the brain.Young male adults with Autism Spectrum Disorders (18-30 years)MedDRA version: 16.1Level: LLTClassification code 10003808Term: Autistic disorderSystem Organ Class: 100000004852Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]
EUCTR2014-000586-45-BEKU Leuven40
Completed
N/A
Intranasal Oxytocin for the Treatment of Autism Spectrum DisordersAutism Spectrum Disorders
NCT01337687Montefiore Medical Center19
Completed
Phase 2
Single Dose Intranasal Oxytocin and Cognitive Effects in AutismAutism Spectrum Disorders
NCT02493426University of Minnesota27